PI3K Pathway: Targeting Ovarian Cancer Therapeutics
Received Date: Dec 01, 2025 / Published Date: Dec 29, 2025
Abstract
The PI3K pathway is a critical signaling cascade frequently dysregulated in ovarian cancer, driving proliferation, survival, and resistance to therapy. Targeting this pathway offers a promising therapeutic strategy, with several PI3K inhibitors showing activity. Understanding PI3K isoforms and resistance mechanisms is key. The PI3K/AKT/mTOR pathway regulates tumorigenesis and progression. PIK3CA mutations are common, emphasizing isoform-specific targeting. Preclinical studies show efficacy for novel inhibitors, and research addresses resistance via combinations. Clinical trials are evaluating PI3K inhibitors in recurrent disease. The pathway’s role in the tumor microenvironment and chemoresistance is under investigation. Isoform-selective inhibitors aim for improved efficacy and safety.
Citation: Wright DN (2025) PI3K Pathway: Targeting Ovarian Cancer Therapeutics. Current Trends Gynecol Oncol 10: 305.
Copyright: 漏 2025 Dr. Nathan Wright This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
Select your language of interest to view the total content in your interested language
Share This Article
Recommended Journals
Open Access Journals
Article Usage
- Total views: 275
- [From(publication date): 0-0 - Apr 09, 2026]
- Breakdown by view type
- HTML page views: 215
- PDF downloads: 60
